RSV

2023 - 3 - 15

GSK drives RSV awareness to center court with Magic Johnson (Endpoints News)

Magic Johnson is picking up a familiar position and running point again, this time on GSK's new respiratory syncytial virus (RSV) awareness campaign.

The campaign is also running on Instagram and Facebook. Magic Johnson is picking up a familiar position and running point again, this time on GSK’s new respiratory syncytial virus (RSV) awareness campaign. Johnson is leading the team effort to make sure older adults know about the virus, and its risks and symptoms, in the “Sideline RSV” initiative.

Post cover
Image courtesy of "Business Wire"

GSK and Earvin “Magic” Johnson Partner to Raise Awareness of ... (Business Wire)

Adults at highest risk for severe RSV infection include older adults and adults with chronic heart and lung disease.

Symptoms and Care. For Healthcare Providers. - Centers for Disease Control and Prevention. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. RSV in Older Adults and Adults with Chronic Medical Conditions. Accessed March 2023. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and any impacts of the COVID-19 pandemic. RSV is a common contagious virus affecting the lungs and breathing passages.1,2 It is one of the major remaining infectious diseases for which there is no vaccine or specific treatment available for adults. Sideline RSV is a health education campaign to help older adults and their loved ones know the risks of respiratory syncytial virus (RSV). The Sideline RSV campaign will include a website with a message from Johnson and information about RSV, social media content, and community-focused events. “My health is a top priority, yet like so many others, I was unaware that older adults are one of the highest risk groups for severe RSV infection, no matter how healthy they feel,” said Johnson. Johnson will help spark important conversations and help educate around the risks of RSV among older adults.

Monoclonal Antibody Treatments Prevent RSV Infection Among ... (Infectious Disease Advisor)

Motavizumab, nirsevimab, and palivizumab were associated with significant protection against RSV infection among infants and children.

Of the active interventions, motavizumab was associated with lower risk for ICU transfer compared with palivizumab (OR, 0.47; 95% CI, 0.23-0.97). In addition, fewer motavizumab recipients required mechanical ventilation compared with placebo (OR, 0.14; 95% CI, 0.03-0.57) or palivizumab (OR, 0.23; 95% CI, 0.06-0.83) recipients. [Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801583). Of the mAb treatments evaluated for RSV prevention, motavizumab was favored over palivizumab (OR, 0.52; 95% CI, 0.32-0.86). Outcomes were compared between patients who received monoclonal antibody (mAbs) and those who received placebo. 2023;6(2):e230023. Further analysis showed a decreased risk for intensive care unit (ICU) admission among patients who received either nirsevimab (OR, 0.04; 95% CI, 0.00-0.81), motavizumab (OR, 0.23; 95% CI, 0.09-0.59), or palivizumab (OR, 0.50; 95% CI, 0.26-0.95) compared with those who received placebo. The final analysis included a total of 15 RCTs, representing 18,395 patients. There also was a decreased risk for RSV infection observed among patients who received motavizumab (OR, 0.17; 95% CI, 0.12-0.23), nirsevimab (OR, 0.24; 95% CI, 0.16-0.37), or palivizumab (OR, 0.32; 95% CI, 0.22-0.47) compared with those who received placebo. Patients who received motavizumab (OR, 0.12; 95% CI, 0.07-0.19), nirsevimab (OR, 0.13; 95% CI, 0.04-0.39), or palivizumab (OR, 0.18; 95% CI, 0.09-0.37) were less likely to require supplemental oxygen compared with placebo recipients. The researchers specifically searched for studies comprising infants younger than 6 months with chronic lung disease of prematurity or congenital heart disease. The researchers found that the risk for hospitalization due to RSV infection was decreased among patients who received either nirsevimab (odds ratio [OR], 0.25; 95% CI, 0.13-0.47) or palivizumab (OR, 0.45; 95% CI, 0.34-0.60) compared with those who received placebo.

Explore the last week